Roche lines up at the FDA's 10-yard line with $1.7B Igny­ta buy­out

Can­cer drug pow­er­house Roche $RHH­BY has swooped in to buy Igny­ta $RXDX for $1.7 bil­lion, putting the phar­ma gi­ant in di­rect com­pe­ti­tion with Loxo On­col­o­gy $LOXO and its new part­ners at Bay­er.

Igny­ta has been grab­bing the at­ten­tion of a boom­ing field with its work in ROS1 and NTRK fu­sion-pos­i­tive tu­mors, win­ning the FDA’s break­through sta­tus last May. And it’s en­gaged in a piv­otal Phase II study for its lead drug en­trec­tinib that could put Roche on the 10 yard line at the FDA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.